Actively Recruiting
Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes
Led by Cohen Global, Ltd. · Updated on 2026-01-14
54
Participants Needed
1
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Multiple Dose, Randomized, Placebo-controlled, Dose-escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered MD-18 for healthy subjects with overweight or obesity
CONDITIONS
Official Title
Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects aged 18-70 years, both genders
- BMI 25-34.9 for cohorts 1-6, 30.0-44.9 for cohort 7
- HbA1c below 6.5%
- Healthy based on medical history, exam, vital signs, lab tests, cardiac and respiratory assessments
- Male subjects with female partners of childbearing potential must use approved contraception
- Female subjects of childbearing potential must have negative pregnancy test and use contraception
- Female subjects of non-childbearing potential (tubal ligation, hysterectomy, or postmenopausal)
- Written informed consent and willingness to comply with study procedures
You will not qualify if you...
- History of excessive alcohol use or recreational drug use within past 3 months or failed drug screen
- Pregnant or breastfeeding within 6 months of screening
- Significant recent changes in eating habits or exercise routine
- Evidence of eating disorders
- More than 5% weight change in past 3 months
- Bariatric surgery within past 5 years
- Moderate renal impairment (glomerular filtration rate below 60)
- Liver function tests more than twice upper limit of normal
- Diseases affecting metabolism or ingestive behavior as determined by investigator
- Use of medications affecting body weight within past 3 months unless dose stable with weight stability
- Clinically significant abnormalities on physical exam or lab tests
- History or evidence of certain cardiac conditions or family history of Long QT Syndrome
- Use of drugs of abuse within past 3 months
- Participation in another investigational drug trial within 1 month prior to dosing
- Positive test for hepatitis B, hepatitis C, HIV, or syphilis infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sheba Medical Center
Ramat Gan, Please Select, Israel, 522651
Actively Recruiting
Research Team
M
Michael Zemel, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here